Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

被引：4

作者：

Harrison, Claire ^{[1
]}

Nangalia, Jyoti ^{[2
,3
,4
]}

Boucher, Rebecca H. ^{[5
]}

Jackson, Aimee ^{[5
]}

Yap, Christina ^{[5
,6
]}

O'Sullivan, Jennifer ^{[7
,8
,9
]}

Fox, Sonia ^{[10
]}

Ailts, Isaak ^{[11
]}

Dueck, Amylou C. ^{[12
]}

Geyer, Holly L. ^{[11
]}

Mesa, Ruben ^{[13
]}

Dunn, William ^{[4
]}

Nadezhdin, Eugene ^{[3
]}

Curto-Garcia, Natalia ^{[7
]}

Green, Anna ^{[14
]}

Wilkins, Bridget ^{[7
]}

Coppell, Jason ^{[15
]}

Laurie, John ^{[16
]}

Garg, Mamta ^{[17
]}

Ewing, Joanne ^{[18
]}

Knapper, Steve ^{[19
]}

Crowe, Josephine ^{[20
]}

Koutsavlis, Ioannis ^{[21
]}

Godfrey, Anna L. ^{[22
]}

Arami, Siamak ^{[23
]}

Drummond, Mark W. ^{[24
]}

Byrne, Jennifer ^{[22
]}

Clark, Fiona J. ^{[25
,26
]}

Mead-Harvey, Carolyn ^{[12
]}

Baxter, Joanna E. ^{[27
]}

McMullin, Mary Frances ^{[28
]}

Mead, Adam J. ^{[8
,9
,29
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England

[2] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England

[3] Wellcome Sanger Inst Hinxton, Hinxton, Cambs, England

[4] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England

[5] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England

[6] Inst Canc Res, Clin Trials & Stat Unit, London, England

[7] Guys & St Thomas NHS Fdn Trust, London, England

[8] Univ Oxford, Med Res Council Weatherall Inst Mol Med, Oxford, England

[9] Univ Oxford, NIHR Biomed Res Ctr, Oxford, England

[10] Univ Birmingham, Clin Trials Unit, Canc Res UK, Birmingham, W Midlands, England

[11] Mayo Clin, Dept Internal Med, Scottsdale, AZ USA

[12] Mayo Clin, Dept Quantitat Hlth Sci, Scottsdale, AZ USA

[13] UT Hlth San Antonio, Mays Canc Ctr, San Antonio, TX USA

[14] Guys & St ThomasNHS Fdn Trust, Dept Histopathol, London, England

[15] Royal Devon & Exeter Hosp, Exeter, Devon, England

[16] Worthing Dist Hosp, Worthing, England

[17] Univ Hosp Leicester, Leicester, Leics, England

[18] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England

[19] Cardiff Univ, Sch Med, Cardiff, Wales

[20] Royal United Hosp, Bath, Avon, England

[21] Western Gen Hosp, Lothian Hlth Board, Edinburgh, Midlothian, Scotland

[22] Cambridge Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Cambridge, England

[23] London North West Univ Healthcare NHS Trust, Harrow, Middx, England

[24] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[25] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Birmingham, W Midlands, England

[26] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Cambridge, England

[27] Cambridge Blood & Stem Cell Biobank NHS BT Cambri, Haematol, Cambridge, England

[28] Queens Univ, Ctr Med Educ, Belfast, Antrim, North Ireland

[29] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Canc & Haematol Ctr, Oxford, England

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-157273

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1781 / 1783

页数：3

共 50 条

[21] Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial
Verstovsek, Srdan
Kiladjian, Jean-Jacques
Griesshammer, Martin
Masszi, Tamas
Durrant, Simon T. S.
Passamonti, Francesco
Harrison, Claire N.
Pane, Fabrizio
Zachee, Pierre
Mesa, Ruben A.
He, Shui
Jones, Mark
Garrett, William M.
Li, Jingjin
Pirron, Ulrich
Lawniczek, Tomasz
Vannucchi, Alessandro M.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[22] RESPONSE: A randomized, open-label, phase III study of ruxolitinib in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU).
Verstovsek, Srdan
Kiladjian, Jean-Jacques
Sandor, Victor
Lukawy, Jacek
Li, Jingjin
He, Shui
Garrett, William M.
Malek, Kamel
Pirron, Ulrich
Mookerjee, Bijoyesh
Vannucchi, Alessandro M.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[23] A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)
Vianelli, Nicola
Benevolo, Giulia
Vannucchi, Alessandro
Harrison, Claire N.
Loschi, Michael
Al-Ali, Haifa Kathrin
Bonifacio, Massimiliano
Cervantes, Francisco
Wrobel, Tomasz
Barosi, Giovanni
Kiladjian, Jean-Jaques
Verstovsek, Srdan
Mesa, Ruben A.
Rose, Shelonitda
Gharpure, Vishwanath
Hernandez, Christopher
Zhang, Jun
Passamonti, Francesco
BLOOD, 2021, 138
[24] Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib With Best Available Therapy in Hydroxyurea-Resistant/Intolerant Patients With Polycythemia Vera
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 4 - 6
[25] Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy
Harrison, Claire N.
Mesa, Ruben A.
Kiladjian, Jean-Jacques
Al-Ali, Haifa-Kathrin
Gisslinger, Heinz
Knoops, Laurent
Squier, Margaret
Sirulnik, Andres
Mendelson, Estella
Zhou, Xiaolei
Copley-Merriman, Catherine
Hunter, Deborah S.
Levy, Richard S.
Cervantes, Francisco
Passamonti, Francesco
Barbui, Tiziano
Barosi, Giovanni
Vannucchi, Alessandro M.
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (02) : 229 - 239
[26] COST EFFECTIVENESS OF RUXOLITINIB VERSUS BEST AVAILABLE THERAPY FOR THE TREATMENT OF MYELOFIBROSIS FROM PUBLIC HEALTH PERSPECTIVE IN CHILE
Rojas, R.
Balmaceda, C.
Vargas, C.
Espinoza, M. A.
VALUE IN HEALTH, 2016, 19 (07) : A590 - A590
[27] Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Hans Michael Kvasnicka
Jürgen Thiele
Carlos E. Bueso-Ramos
William Sun
Jorge Cortes
Hagop M. Kantarjian
Srdan Verstovsek
Journal of Hematology & Oncology, 11
[28] Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Kvasnicka, Hans Michael
Thiele, Juergen
Bueso-Ramos, Carlos E.
Sun, William
Cortes, Jorge
Kantarjian, Hagop M.
Verstovsek, Srdan
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[29] Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Richard G. Wunderink
Evangelos J. Giamarellos-Bourboulis
Galia Rahav
Amy J. Mathers
Matteo Bassetti
Jose Vazquez
Oliver A. Cornely
Joseph Solomkin
Tanaya Bhowmick
Jihad Bishara
George L. Daikos
Tim Felton
Maria Jose Lopez Furst
Eun Jeong Kwak
Francesco Menichetti
Ilana Oren
Elizabeth L. Alexander
David Griffith
Olga Lomovskaya
Jeffery Loutit
Shu Zhang
Michael N. Dudley
Keith S. Kaye
Infectious Diseases and Therapy, 2018, 7 : 439 - 455
[30] Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy
Harrison, Claire N.
Kiladjian, Jean-Jacques
Al-Ali, Haifa Kathrin
Gisslinger, Heinz
Knoops, Laurent
Waltzman, Roger J.
Mendelson, Estella T.
Zhou, Xiaolei
Copley-Merriman, Catherine
Hunter, Deborah S.
Levy, Richard S.
Cervantes, Francisco
Passamonti, Francesco
Vannucchi, Alessandro M.
Barbui, Tiziano
Barosi, Giovanni
BLOOD, 2011, 118 (21) : 361 - 362

← 1 2 3 4 5 →